Luminex (LMNX) Hits New 1-Year High and Low at $26.48

Luminex Co. (NASDAQ:LMNX)’s share price hit a new 52-week high and low during trading on Thursday . The company traded as low as $26.48 and last traded at $26.30, with a volume of 9809 shares. The stock had previously closed at $26.25.

A number of equities research analysts have issued reports on LMNX shares. BidaskClub upgraded Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 19th. BTIG Research set a $26.00 price target on Luminex and gave the stock a “buy” rating in a research note on Tuesday, May 8th. ValuEngine upgraded Luminex from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Deutsche Bank upgraded Luminex from a “sell” rating to a “hold” rating and set a $22.00 price target for the company in a research note on Monday, May 7th. Finally, William Blair reiterated a “market perform” rating on shares of Luminex in a research note on Tuesday, February 13th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $24.00.

The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 29.89, a PEG ratio of 2.17 and a beta of 0.11.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, May 7th. The medical instruments supplier reported $0.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.08. The firm had revenue of $82.60 million during the quarter, compared to analyst estimates of $80.52 million. Luminex had a return on equity of 8.07% and a net margin of 10.60%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 earnings per share. research analysts predict that Luminex Co. will post 0.75 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 13th. Stockholders of record on Friday, June 22nd will be given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.88%. Luminex’s payout ratio is 26.37%.

In related news, SVP Todd C. Bennett sold 2,235 shares of Luminex stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $25.95, for a total value of $57,998.25. Following the completion of the transaction, the senior vice president now owns 21,309 shares in the company, valued at $552,968.55. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB purchased a new position in Luminex in the first quarter worth about $241,000. Legal & General Group Plc lifted its stake in Luminex by 9.7% in the first quarter. Legal & General Group Plc now owns 86,215 shares of the medical instruments supplier’s stock worth $1,817,000 after purchasing an additional 7,642 shares during the last quarter. Millennium Management LLC lifted its stake in Luminex by 10.4% in the first quarter. Millennium Management LLC now owns 1,038,865 shares of the medical instruments supplier’s stock worth $21,889,000 after purchasing an additional 98,190 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Luminex in the first quarter worth about $826,000. Finally, Carleon Capital Partners LLC lifted its stake in Luminex by 11.6% in the first quarter. Carleon Capital Partners LLC now owns 51,710 shares of the medical instruments supplier’s stock worth $1,090,000 after purchasing an additional 5,360 shares during the last quarter. Institutional investors own 80.19% of the company’s stock.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply